These results were consistent with those obtained from the SUSY HNSCC patient cohort (109 HNSCC and 33 ANCTs), where IGF2BP2 protein expression was upregulated in HNSCC and positively associated with tumor size, clinical stage, and CLN metastasis, without any statistical difference observed in pathological grade (Fig. 2L-R). The gene discussed is IGF2BP2; the disease is head and neck squamous cell carcinoma.